Novo cuts Wegovy prices with US subscription plan to counter Lilly
Synopsis
Novo cuts Wegovy prices with subscription plans to boost access and counter Lilly
Novo Nordisk is rolling out discounted subscription plans for its obesity drug Wegovy in the US, cutting prices by up to 30% for self-pay patients as it looks to regain momentum against Eli Lilly in an intensifying price war. The move reflects a broader shift toward direct-to-consumer healthcare and growing pressure on drugmakers to improve affordability and access.
Key highlights
- Novo Nordisk launches discounted Wegovy subscription plans in the US
- Prices cut by up to 30% for self-pay patients
- Move aims to counter Eli Lilly’s Zepbound competition
- Telehealth platforms to drive direct-to-consumer expansion
- Pricing pressure intensifies in obesity drug market
Wegovy price cut: What happened
Novo Nordisk will roll out discounted subscription plans for its obesity drug Wegovy in the United States, targeting patients who pay out of pocket.
The programme offers fixed monthly pricing for three-, six-, and 12-month plans, with longer subscriptions providing deeper discounts. Prices for Wegovy injection pens range from $329 to $249 per month, compared with the standard $349 rate. The oral version is priced between $289 and $249 per month.
The plans will be available via telehealth platforms including Ro, WeightWatchers and LifeMD, with more partners expected to join.
Price war dynamics: Why this matters
The move underscores intensifying competition between Novo Nordisk and Eli Lilly in the fast-growing obesity drug market.
Novo has already cut prices more aggressively than Lilly, as prescriptions for Wegovy lag behind Lilly’s rival drug Zepbound. Analysts warn that deeper discounts could pressure margins, even as companies try to expand patient access and retain long-term users.
At the same time, both drugmakers are shifting toward direct-to-consumer and telehealth-driven distribution to steer patients away from cheaper compounded alternatives.
Company strategy: Official statements
Novo said the subscription model reflects changing patient behaviour, with more users seeking predictable pricing and easier access to treatment.
“We’re seeing the patient evolving into the consumer of health,” a senior company executive said, highlighting demand for simple payment structures and long-term treatment continuity.
Telehealth partners echoed that both Novo and Lilly are adopting strategies similar to consumer industries, focusing on accessibility and pricing transparency.
Market context: Sector performance
The broader obesity drug market is undergoing rapid transformation as pricing competition intensifies.
Lilly’s Zepbound pricing starts at $299 per month for lower doses and rises with higher strengths, putting pressure on Novo’s market share. Meanwhile, both companies are expanding digital distribution channels to sustain growth.
Competition is also increasing as regulators review new obesity treatments, including Lilly’s oral drug candidate, which is expected to receive a decision soon.
Australia angle: What it means locally
While the subscription model is currently limited to the US, the pricing war could have downstream effects in Australia.
Lower global pricing benchmarks may eventually influence Pharmaceutical Benefits Scheme (PBS) negotiations and private market pricing. Increased competition could also improve long-term access to obesity treatments in Australia, where demand is rising but affordability remains a constraint.
What happens next
Novo Nordisk is expected to expand its telehealth partnerships and refine pricing strategies as competition with Eli Lilly intensifies.
Further price adjustments across the sector are likely, especially if new drug approvals accelerate competition. The outcome of regulatory decisions on upcoming obesity treatments could also reshape pricing dynamics in the coming months.
FAQs
Q1: Why is Novo Nordisk cutting Wegovy prices?
To attract more self-pay patients, compete with Eli Lilly, and expand access through subscription-based pricing.
Q2: How much cheaper is the new Wegovy plan?
Prices are up to 30% lower, depending on the subscription duration.
Q3: Where can patients access the discounted plans?
Through telehealth platforms such as Ro, WeightWatchers and LifeMD.
Q4: How does this affect the obesity drug market?
It signals a growing price war, increased competition, and a shift toward direct-to-consumer healthcare models.
Follow Inspirepreneur Magazine for the business news.
I write about markets, money, and the macro forces that move them. Passionate about turning complex economic trends into sharp, easy-to-understand stories. Off the clock, it’s hip hop, rock, reggae -- and a mix of cricket and basketball.
